Dopa And NotTamae Ohye
List of bibliographic references
Number of relevant bibliographic references: 31.Ident. | Authors (with country if any) | Title |
---|---|---|
000040 | Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Tessa Snoeren [Pays-Bas] ; James B. Koprich [Canada] ; Michael P. Hill [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] | Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque |
000353 | Bernard Ng [Canada] ; Samantha Palmer [Canada] ; Rafeef Abugharbieh [Canada] ; Martin J. Mckeown [Canada] | Focusing Effects of L-Dopa in Parkinson's Disease |
000537 | Jorge Guridi [Espagne] ; Jose A. Obeso [Espagne] ; Maria C. Rodriguez-Oroz [Espagne] ; Andres A. Lozano [Canada] ; Miguel Manrique [Espagne] ; Philip A. Starr ; Julie G. Pilitsis ; Roy A. E. Bakay ; Marwan I. Hariz ; Ventura Arjona ; Jose G. Martin-Rodriguez | L-DOPA-INDUCED DYSKINESIA AND STEREOTACTIC SURGERY FOR PARKINSON'S DISEASE. Commentaries |
000713 | Jon Doan [Canada] ; Ian Q. Whishaw [Canada] ; Sergio M. Pellis [Canada] ; Oksana Suchowersky [Canada] ; Lesley A. Brown [Canada] | Motor deficits in parkinsonian reaching : Dopa-sensitivity influenced by real-world task constraint |
000917 | Alan L. Whone [Royaume-Uni] ; Ray L. Watts [États-Unis] ; A. Jon Stoessl [Canada] ; Margaret Davis [États-Unis] ; Sven Reske [Allemagne] ; Claude Nahmias [Canada] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Maria J. Ribeiro [France] ; Philippe Remy [France] ; Werner Poewe [Autriche] ; Robert A. Hauser [États-Unis] ; David J. Brooks [Royaume-Uni] | Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study |
000952 | Yoshiaki Furukawa [Canada] | Genetics and biochemistry of dopa-responsive dystonia: Significance of striatal tyrosine hydroxylase protein loss |
000C12 | O. Rascol [France] ; D. J. Brooks [Royaume-Uni] ; A. D. Korczyn [Israël] ; P. P. De Deyn [Belgique] ; C. E. Clarke [Royaume-Uni] ; A. E. Lang [Canada] | A five-year study of the incidence of dyskinesia in patients with early parkinson's disease who were treated with ropinirole or levodopa |
000D85 | D. J. Doudet [Canada] ; G. L. Y. Chan [Canada] ; J. E. Holden [États-Unis] ; K. S. Morrison [Canada] ; R. J. Wyatt [États-Unis] ; T. J. Ruth [Canada] | Effects of catechol-O-methyltransferase inhibition on the rates of uptake and reversibility of 6-fluoro-L-dopa trapping in MPTP-induced Parkinsonism in monkeys |
000E13 | P. Sandor [Canada] ; A. E. Lang [Canada] ; S. Singal [Canada] ; C. Augus [Canada] | Remoxipride in the treatment of levodopa-induced psychosis |
000E22 | J.-J. Soghomonian [Canada] ; S. Pedneault [Canada] ; P. J. Blanchet [Canada] ; M. Goulet [Canada] ; T. Di Paolo [Canada] ; P. J. Bedard [Canada] | L-DOPA regulates glutamate decarboxylases mRNA levels in MPTP-treated monkeys |
000E50 | A. E. Lang [Canada] ; P. Sandor ; J. Duff [Canada] | Remoxipride in Parkinson's disease : differential response in patients with dyskinesias fluctuations versus psychosis |
000E52 | H. Kuwabara [Canada] ; P. Cumming ; Y. Yasuhara ; G. C. Leger ; M. Guttman ; M. Diksic ; A. C. Evans ; A. Gjedde | Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease |
000E58 | F. Calon [Canada] ; M. Goulet [Canada] ; P. J. Blanchet ; J. C. Martel [Canada] ; M. F. Piercey ; P. J. Bedard ; T. Di Paolo [Canada] | Levodopa or D2 agonist induced dyskinesia in MPTP monkeys : correlation with changes in dopamine and GABAA receptors in the striatopallidal complex |
000E69 | P. J. Bedard [Canada] ; B. Gomez-Mancilla [Canada] ; P. Blanchet [Canada] ; R. Grondin [Canada] ; T. Dipaolo [Canada] ; SETHY ; PIERCEY ; CHASE ; WISE ; PERLMUTTER ; RANHOSKY | Dopamine-receptor families and the treatment of Parkinson's disease. Discussion |
000F10 | P. J. Blanchet [Canada] ; R. Boucher [Canada] ; P. J. Bedard | Excitotoxic lateral pallidotomy does not relieve L-DOPA-induced dyskinesia in MPTP parkinsonian monkeys |
000F22 | A. Gjedde [Canada] ; G. C. Leger ; P. Cumming ; Y. Yasuhara ; A. C. Evans ; M. Guttman ; H. Kuwabara | Striatal L-DOPA decarboxylase activity in Parkinson's disease in vivo : implications for the regulation of dopamine synthesis |
000F59 | L. Rioux [Canada] ; C. Gagnon ; D. P. Gaudin [Canada] ; T. Di Paolo ; P. J. Bedard [Canada] | A fetal nigral graft prevents behavioral supersensitivity associated with repeated injections of L-dopa in 6-OHDA rats. Correlation with D1 and D2 receptors |
000F77 | G. L.-Y. Chan [Canada] ; K. Scott Morrison ; J. E. Holden ; T. J. Ruth | Plasma L-[18F]6-Fluorodopa input function : a simplified method |
001010 | M. Cordes [Canada] ; B. J. Snow ; H. Takahashi ; P. Schofield ; S. Cooper ; V. Sossi ; S. Morrison ; D. B. Calne | L-18F-DOPA-PET bei Parkinson-Plus-Syndromen zum Nachweis einer gestörten präsynaptischen dopaminergen Funktion |
001031 | B. Gomez-Mancilla [Canada] ; P. J. Bedard | Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-DOPA in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys |
001048 | N. R. C. Campbell ; D. Rankine ; A. E. Goodridge ; B. B. Hasinoff ; M. Kara | Sinemet-ferrous sulphate interaction in patients with Parkinson's disease |
001070 | J. K. C. Tsui ; R. F. Peppard ; K. C. Petruk ; G. Allen ; R. S. Burns ; D. B. Calne | Decreased efficay of levodopa with carbidopa in parkinsonian patients after adrenal-to-caudate implants |
001093 | G. S. Robertson ; D. G. Herrera ; M. Dragunow ; H. A. Robertson | L-DOPA activates c-fos in the striatum ipsilateral to a 6-hydroxydopamine lesion of the substantia nigra |
001117 | D. Riley ; A. E. Lang | Practical application of a low-protein diet for Parkinson's disease |
001126 | P. Falardeau ; S. Bouchard ; P. J. Bedard ; R. Boucher ; T. Di Paolo | Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2dopamine agonists in MPTP monkeys |
001130 | E. C. Wolters ; J. C. Kebabian ; M. Guttman ; E. Mak ; B. D. Pate ; D. B. Calne | A new device for the quantitative assessment of dopaminergic drug effects in unilateral MPTP-lesioned monkeys |
001138 | J. A. Sharpe ; W. A. Fletcher ; A. E. Lang ; D. H. Zackon | Smooth pursuit during dose-related on-off fluctuations in Parkinson's disease |
001147 | H. A. Robertson ; G. S. Robertson | Hypothesis. Combined L-dopa and bromocriptine therapy for Parkinson's disease: a proposed mechanism of action |
001167 | C. B. Bozek ; O. Suchowersky ; S. Purves ; S. Calne ; D. B. Calne | Sinemet in Parkinson's disease: efficacy with and without food |
001176 | E. Lau ; K. Waterman ; R. Glover ; M. Schulzer ; D. B. Calne | Effect of antacid on levodopa therapy |
001184 | P. J. Bedard ; T. Di Paolo ; P. Falardeau ; R. Boucher | Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-Parkinsonian monkeys. Correlation with [3H]spiperone binding |
![]() | This area was generated with Dilib version V0.6.29. | ![]() |